ClinicalTrials.gg
Enrolling by invitationNCT05113069Updated Dec 6, 2023

A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas

A Phase 1 interventional study of SHR-A1912 in B Cell Lymphoma, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 7 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
170
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Planned enrollment
33rd of 273
170 · median 30
Started
2021
with 30 others
Phase 1
124 of 283
57 open now
Primary completion
2024-03
later than 7 of 145 live
Registered
127th of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 33rd largest by planned enrollment of the 273 interventional ones that give a count, is one of 31 that started in 2021, is one of 124 in phase 1, reaches primary completion later than 7 of the 145 other live ones, and was the 127th registered.

Lymphoma, B-Cell

886 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

To assess the safety and tolerability of SHR-A1912 in patients with B cell lymphoma, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1912.

03

Conditions studied

  • B Cell Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater than or equal to18 years old, male or female;
  2. (ECOG) performance status is 0 to 1;
  3. >12 weeks;
  4. or cytologically confirmed B cell lymphoma;
  5. disease after at least 1 prior treatment regimen;
  6. At least one measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or one measurable extra nodal lesion, defined as > 1.0 cm in its longest diameter (no need for dose escalation stage).

Exclusion criteria

Exclusion Criteria:

  1. Received stem cell transplantation within 12 weeks before the first study treatment; previously received allogeneic stem cell transplantation; received Car-T cell therapy within 12 weeks before the first study treatment;
  2. History of recent major surgery or severe trauma within 4 weeks before the first study treatment;
  3. Received anti-tumour treatment within 2 weeks before the first study treatment;
  4. Central nervous system (CNS) infiltration;
  5. Active infection with or ;
  6. History of immunodeficiency, including serotest positive, or other acquired or congenital immunodeficiency diseases, and active tuberculosis;
  7. Active infection or unexplained fever>38.5℃;
  8. History of severe cardiovascular disease.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Treatment group

    SHR-A1912

    Drug: SHR-A1912

Interventions

  • DrugSHR-A1912

    SHR-A1912, dose escalation and expansion.

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Time frame: 21 Days after the 1st dosing (first cycle)

  2. Dose Limited Toxicity (DLT)

    Time frame: 21 Days (first cycle)

  3. Maximum tolerable dose (MTD)

    Time frame: 21 Days (first cycle)

  4. Recommended phase II dose (RP2D)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Adverse Events

    Time frame: 12 weeks after the last dose

  2. Time of maximum observed plasma concentration (Tmax) of SHR-1912

    Time frame: 21 days after last dose

  3. Maximum observed plasma concentration (Cmax) of SHR-1912

    Time frame: 21 days after last dose

  4. Area under the plasma concentration time curve (AUC) of SHR-1912

    Time frame: 21 days after last dose

  5. Anti-drug antibody (ADA) of SHR-A1912

    Time frame: 12 weeks after last dose

  6. Complete Response Rate (CR)

    Time frame: Up to approximately 2 years

  7. Objective Response Rate (ORR)

    Time frame: Up to approximately 2 years

  8. Duration of Response (DoR)

    Time frame: Up to approximately 2 years

  9. Disease Control Rate (DCR)

    Time frame: Up to approximately 2 years

  10. Progression-Free Survival (PFS)

    Time frame: Up to approximately 2 years

  11. Overall Survival (OS)

    Time frame: Up to approximately 3 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Mar 2024, 27 months after the start.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 27 months is below that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2021
First posted
Nov 9, 2021
StartActual
Dec 22, 2021
Primary completionEst.
Mar 31, 2024
CompletionEst.
Mar 30, 2025
Last update
Dec 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05113069
Responsible party
Sponsor
First posted
Nov 9, 2021
Start date
Dec 22, 2021
Primary completion
Mar 31, 2024 (estimated)
Completion
Mar 30, 2025 (estimated)
Last update
Dec 6, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion